SK Biopharmaceuticals Co., Ltd. 326030
KRX · South Korea · Health Technology
KRW 76,700.00+2,300.00 (+3.09%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Deal valued at up to $314.8 million, including milestones, with a separate $2.2 million strategic equity investmentCollaboration leverages 1STBIO’s Type 2 LRRK2/c-Abl dual inhibitor to advance next-generation Parkinson's treatment YONGIN, South Korea, September 17, 2026 — 1ST Biotherapeutics, Inc. (“1STBIO”) and SK Biopharmaceuticals Co., Ltd. (“SKBP”) today announced that they have entered into an exclusive global licensing agreement and strategic equity investment (SI) partnership to advance 1
Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
Biohaven said the FDA paused new patient enrollment in the BHV7000-303 trial after nonclinical studies in rodents identified a specific metabolite.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.